Integrated Oncology is an integral part of the LabCorp team that brings together world-class diagnostics and drug development capabilities so patients have day one access to companion diagnostics and associated FDA approved therapies. Together, we are uniquely positioned at the intersection of research and patient care to enable more precise and individualized health care. Our menu of molecular, next generation sequencing and immuno-oncology assays are at the forefront of precision medicine, matching the right patient with the best treatment.
Latest in Precision Medicine
Video (see below): Covance Chief Scientific Officer Steve Anderson speaks about the importance of partnerships in delivering on the promise of precision medicine.
Video (see below): At ASCO 2019, LabCorp's Senior Director for Molecular Oncology Anjen Chenn, MD Ph.D, speaks about FGFR testing solutions from QIAGEN and how it works. He also answers the question: Why does Day One Lab Readiness matter?
Video (see below): At ASCO 2019, Tom Turi speaks about companion diagnostics and the benefits for labs and patients gained from the Day One Lab Readiness program from QIAGEN.
Video (see below): LabCorp Chief Medical Officer Brian Caveney Speaks about the Economics of Precision Medicine at the Precision Medicine World Conference at Duke University
Background and video: Companion diagnostics: Changing the way patient care is provided